Grova Mauro, Crispino Federica, Maida Marcello, Renna Sara, Mannino Mariella, Casà Angelo, Rizzuto Giulia, Macaluso Fabio Salvatore, Orlando Ambrogio
Department of Health Promotion Sciences Maternal and Infant Care, Section of Gastroenterology and Hepatology, Internal Medicine and Medical Specialties, PROMISE, University of Palermo.
Department of Medicine, Inflammatory Bowel Disease Unit, A.O.O.R., "Villa Sofia-Cervello" Hospital, Palermo.
Eur J Gastroenterol Hepatol. 2022 Jun 1;34(6):607-612. doi: 10.1097/MEG.0000000000002348. Epub 2022 Jan 31.
We evaluated an on-demand ferric carboxymaltose (FCM) infusion strategy in inflammatory bowel disease (IBD) patients with iron deficiency anemia (IDA).
The primary outcome was the response rate to single or multiple FCM infusions after 12 months. Secondary outcomes were the response rate to a single FCM infusion after 3 months and the FCM safety profile.
We retrospectively included 185 IBD patients who received at least one FCM infusion of 500 mg, between 2015 and 2018. FCM was administered to patients with Hb ≤10 g/dL and hypoferritinemia and repeated according to the physician's assessment. Complete response (CR) was defined as Hb ≥12 g/dL (≥13 g/dL for men) or Hb increase ≥2 g/dL. Partial response (PR) was defined as an Hb increase between 1 and 2 g/dL. A univariate analysis was performed at 3 and 12 months.
After 12 months, the response rate was 75.1% (CR, 48.6%; PR, 26.4%; mean number of FCM infusions, 1.7 ± 1.1). In total 169/185 patients received a single FCM infusion during the first 3 months and 79.2% achieved response (CR, 56.8%; PR, 22.4%). At univariate analysis, no variable was associated with response. No adverse events were reported.
An on-demand strategy was effective and well-tolerated in treating IDA in IBD patients.
我们评估了按需给予羧基麦芽糖铁（FCM）输注策略在缺铁性贫血（IDA）的炎症性肠病（IBD）患者中的应用。
主要结局是12个月后单次或多次FCM输注的缓解率。次要结局是3个月后单次FCM输注的缓解率及FCM的安全性。
我们回顾性纳入了2015年至2018年间接受至少一次500mg FCM输注的185例IBD患者。对血红蛋白（Hb）≤10g/dL且铁蛋白水平低的患者给予FCM，并根据医生评估重复给药。完全缓解（CR）定义为Hb≥12g/dL（男性≥13g/dL）或Hb升高≥2g/dL。部分缓解（PR）定义为Hb升高1至2g/dL。在3个月和12个月时进行单因素分析。
12个月后，缓解率为75.1%（CR为48.6%；PR为26.4%；FCM输注的平均次数为1.7±1.1）。总共169/185例患者在最初3个月内接受了单次FCM输注，79.2%获得缓解（CR为56.8%；PR为22.4%）。单因素分析显示，无变量与缓解相关。未报告不良事件。
按需策略在治疗IBD患者的IDA方面有效且耐受性良好。
